164 related articles for article (PubMed ID: 31639208)
1. Population-based study of the prevalence and management of self-reported high pain scores in patients with non-resected pancreatic adenocarcinoma.
Tung S; Coburn NG; Davis LE; Mahar AL; Myrehaug S; Zhao H; Earle CC; Nathens A; Hallet J
Br J Surg; 2019 Nov; 106(12):1666-1675. PubMed ID: 31639208
[TBL] [Abstract][Full Text] [Related]
2. Population-Level Symptom Assessment Following Pancreaticoduodenectomy for Adenocarcinoma.
Tung S; Davis LE; Hallet J; Mavros MN; Mahar AL; Bubis LD; Hammad A; Zhao H; Earle CC; Barbera L; Coburn NG; ; Siqqidui M; Li Q; Elmi M; Shin E; Hsieh E; Goyert N
JAMA Surg; 2019 Nov; 154(11):e193348. PubMed ID: 31483457
[TBL] [Abstract][Full Text] [Related]
3. Symptom trajectories and predictors of severe symptoms in pancreatic adenocarcinoma at the end-of-life: a population based analysis of 2,538 patients.
Hammad A; Davis LE; Mahar AL; Bubis LD; Zhao H; Earle CC; Barbera L; Hallet J; Coburn NG
HPB (Oxford); 2019 Dec; 21(12):1744-1752. PubMed ID: 31300337
[TBL] [Abstract][Full Text] [Related]
4. Predictors of analgesic efficacy of neurolytic celiac plexus block in patients with unresectable pancreatic cancer: the importance of timing.
Yoon DM; Yoon KB; Baek IC; Ko SH; Kim SH
Support Care Cancer; 2018 Jun; 26(6):2023-2030. PubMed ID: 29344736
[TBL] [Abstract][Full Text] [Related]
5. Has Province-Wide Symptom Screening Changed Opioid Prescribing Rates in Older Patients With Cancer?
Barbera L; Sutradhar R; Chu A; Seow H; Earle CC; O'Brien MA; Dudgeon D; DeAngelis C; Atzema C; Husain A; Liu Y; Howell D
J Oncol Pract; 2017 Nov; 13(11):e927-e934. PubMed ID: 28926291
[TBL] [Abstract][Full Text] [Related]
6. Predicting the risk for aberrant opioid use behavior in patients receiving outpatient supportive care consultation at a comprehensive cancer center.
Yennurajalingam S; Edwards T; Arthur JA; Lu Z; Najera J; Nguyen K; Manju J; Kuriakose L; Wu J; Liu D; Williams JL; Reddy SK; Bruera E
Cancer; 2018 Oct; 124(19):3942-3949. PubMed ID: 30192372
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal Drug Delivery Systems for Refractory Pancreatic Cancer Pain: Observational Follow-up Study Over an 11-Year Period in a Comprehensive Cancer Center.
Carvajal G; Dupoiron D; Seegers V; Lebrec N; Boré F; Dubois PY; Leblanc D; Delorme T; Jubier-Hamon S
Anesth Analg; 2018 Jun; 126(6):2038-2046. PubMed ID: 29543644
[TBL] [Abstract][Full Text] [Related]
8. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis.
Mavros MN; Coburn NG; Davis LE; Mahar AL; Liu Y; Beyfuss K; Myrehaug S; Earle CC; Hallet J
CMAJ; 2019 May; 191(21):E574-E580. PubMed ID: 31133604
[TBL] [Abstract][Full Text] [Related]
9. Echoendoscopic ethanol ablation of tumor combined with celiac plexus neurolysis in patients with pancreatic adenocarcinoma.
Facciorusso A; Di Maso M; Serviddio G; Larghi A; Costamagna G; Muscatiello N
J Gastroenterol Hepatol; 2017 Feb; 32(2):439-445. PubMed ID: 27356212
[TBL] [Abstract][Full Text] [Related]
10. Dyspnea in patients with stage IV non-small cell lung cancer: a population-based analysis of disease burden and patterns of care.
Yan M; Tjong M; Chan WC; Darling G; Delibasic V; Davis LE; Doherty M; Hallet J; Kidane B; Mahar A; Mittmann N; Parmar A; Tan V; Tan H; Wright FC; Coburn NG; Louie AV
J Thorac Dis; 2023 Feb; 15(2):494-506. PubMed ID: 36910044
[TBL] [Abstract][Full Text] [Related]
11. Impact of Pain, Opioids, and the Mu-opioid Receptor on Progression and Survival in Patients With Newly Diagnosed Stage IV Pancreatic Cancer.
Steele GL; Dudek AZ; Gilmore GE; Richter SA; Olson DA; Eklund JP; Zylla DM
Am J Clin Oncol; 2020 Aug; 43(8):591-597. PubMed ID: 32482952
[TBL] [Abstract][Full Text] [Related]
12. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial.
Wong GY; Schroeder DR; Carns PE; Wilson JL; Martin DP; Kinney MO; Mantilla CB; Warner DO
JAMA; 2004 Mar; 291(9):1092-9. PubMed ID: 14996778
[TBL] [Abstract][Full Text] [Related]
13. Patient-Reported Symptom Severity Among 22,650 Cancer Outpatients in the Last Six Months of Life.
Bubis LD; Davis LE; Canaj H; Gupta V; Jeong Y; Barbera L; Li Q; Moody L; Karanicolas PJ; Sutradhar R; Coburn NG; Mahar AL
J Pain Symptom Manage; 2020 Jan; 59(1):58-66.e4. PubMed ID: 31430522
[TBL] [Abstract][Full Text] [Related]
14. Optimal pain management for patients with cancer in the modern era.
Scarborough BM; Smith CB
CA Cancer J Clin; 2018 May; 68(3):182-196. PubMed ID: 29603142
[TBL] [Abstract][Full Text] [Related]
15. Symptom Burden of Nonresected Pancreatic Adenocarcinoma: An Analysis of 10,753 Patient-Reported Outcome Assessments.
Mavros MN; Davis LE; Hallet J; Tung S; Mahar AL; Bubis LD; Hammad A; Zhao H; Earle CC; Barbera L; Coburn NG
Pancreas; 2020 Sep; 49(8):1083-1089. PubMed ID: 32769858
[TBL] [Abstract][Full Text] [Related]
16. Coeliac Plexus Neurolysis For Pancreatic Cancer Patients; Retrospective Analysis Of Shaukat Khanum Memorial Cancer Hospital & Research Centre Experience.
Malik SH; Hafeez H; Malik NH; Rehman Ghafoor AU
J Ayub Med Coll Abbottabad; 2018; 30(4):516-519. PubMed ID: 30632327
[TBL] [Abstract][Full Text] [Related]
17. Intraoperative radiotherapy in the combined-modality management of pancreatic cancer.
Schuricht AL; Spitz F; Barbot D; Rosato F
Am Surg; 1998 Nov; 64(11):1043-9. PubMed ID: 9798766
[TBL] [Abstract][Full Text] [Related]
18. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.
Hank T; Hinz U; Tarantino I; Kaiser J; Niesen W; Bergmann F; Hackert T; Büchler MW; Strobel O
Br J Surg; 2018 Aug; 105(9):1171-1181. PubMed ID: 29738626
[TBL] [Abstract][Full Text] [Related]
19. CT guided neurolytic blockade of the coeliac plexus in patients with advanced and intractably painful pancreatic cancer.
Rosland JH; Geitung JT
Scand J Pain; 2018 Apr; 18(2):247-251. PubMed ID: 29794300
[TBL] [Abstract][Full Text] [Related]
20. Response to Oral Immediate-Release Opioids for Breakthrough Pain in Patients with Advanced Cancer with Adequately Controlled Background Pain.
Azhar A; Kim YJ; Haider A; Hui D; Balankari VR; Epner MC; Park M; Liu DD; Williams J; Frisbee-Hume SE; Allo JA; Bruera E
Oncologist; 2019 Jan; 24(1):125-131. PubMed ID: 30254187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
